JP2003500399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003500399A5 JP2003500399A5 JP2000619786A JP2000619786A JP2003500399A5 JP 2003500399 A5 JP2003500399 A5 JP 2003500399A5 JP 2000619786 A JP2000619786 A JP 2000619786A JP 2000619786 A JP2000619786 A JP 2000619786A JP 2003500399 A5 JP2003500399 A5 JP 2003500399A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- methyl
- alkyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 70
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- 239000000243 solution Substances 0.000 description 35
- -1 cyano, nitro, amino, hydroxyl Chemical group 0.000 description 26
- 125000004430 oxygen atom Chemical group O* 0.000 description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 19
- 150000003839 salts Chemical class 0.000 description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 229910052739 hydrogen Inorganic materials 0.000 description 16
- 239000001257 hydrogen Substances 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- 239000012453 solvate Substances 0.000 description 14
- 229910052731 fluorine Inorganic materials 0.000 description 13
- 125000001153 fluoro group Chemical group F* 0.000 description 13
- 125000000623 heterocyclic group Chemical group 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 238000004949 mass spectrometry Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 125000000753 cycloalkyl group Chemical group 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- 238000001816 cooling Methods 0.000 description 7
- 125000004434 sulfur atom Chemical group 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- 0 *c(c(*)c1*)c(*)c(*CC(O)=O)c1P Chemical compound *c(c(*)c1*)c(*)c(*CC(O)=O)c1P 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 5
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 230000000414 obstructive effect Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 208000023504 respiratory system disease Diseases 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- OQJBFFCUFALWQL-UHFFFAOYSA-N n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)N=NC(=O)N1CCCCC1 OQJBFFCUFALWQL-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- ZZRXVPISIXHDIM-YDULTXHLSA-N 2-(3,4-difluoroanilino)-N-[2-methyl-4-[[(2S)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]methyl]phenyl]acetamide trihydrochloride Chemical compound Cl.Cl.Cl.Cc1cc(CN2CCC[C@H]2CN2CCCC2)ccc1NC(=O)CNc1ccc(F)c(F)c1 ZZRXVPISIXHDIM-YDULTXHLSA-N 0.000 description 2
- XJLYAACHFFNHPV-UHFFFAOYSA-N 2-(3,4-difluoroanilino)-n-[2-methyl-4-(piperazin-1-ylmethyl)phenyl]acetamide;trihydrochloride Chemical compound Cl.Cl.Cl.C=1C=C(NC(=O)CNC=2C=C(F)C(F)=CC=2)C(C)=CC=1CN1CCNCC1 XJLYAACHFFNHPV-UHFFFAOYSA-N 0.000 description 2
- WSBRAHWNJBXXJM-UHFFFAOYSA-N 2-(3,4-difluoroanilino)-n-[2-methyl-5-(piperazin-1-ylmethyl)phenyl]acetamide;trihydrochloride Chemical compound Cl.Cl.Cl.C1=C(NC(=O)CNC=2C=C(F)C(F)=CC=2)C(C)=CC=C1CN1CCNCC1 WSBRAHWNJBXXJM-UHFFFAOYSA-N 0.000 description 2
- KZSNCGDIRIZTIH-UHFFFAOYSA-N 2-(3,4-difluoroanilino)-n-[2-methyl-5-(piperazin-1-ylmethyl)phenyl]ethanethioamide Chemical compound C1=C(NC(=S)CNC=2C=C(F)C(F)=CC=2)C(C)=CC=C1CN1CCNCC1 KZSNCGDIRIZTIH-UHFFFAOYSA-N 0.000 description 2
- HTMZOECRJRQODE-NRFANRHFSA-N 2-(3,4-difluoroanilino)-n-[2-methyl-5-[[(2s)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]methyl]phenyl]acetamide Chemical compound C([C@@H]1CCCN1CC1=CC=C(C(=C1)NC(=O)CNC=1C=C(F)C(F)=CC=1)C)N1CCCC1 HTMZOECRJRQODE-NRFANRHFSA-N 0.000 description 2
- ZVULIZVXYJVIMD-UHFFFAOYSA-N 2-(3-chloro-4-fluoroanilino)-n-(5-hydroxy-2-methylphenyl)acetamide Chemical compound CC1=CC=C(O)C=C1NC(=O)CNC1=CC=C(F)C(Cl)=C1 ZVULIZVXYJVIMD-UHFFFAOYSA-N 0.000 description 2
- CWDFHONQSDKIMI-UHFFFAOYSA-N 2-[3,4-difluoro-n-[(2-methylpropan-2-yl)oxycarbonyl]anilino]acetic acid Chemical compound CC(C)(C)OC(=O)N(CC(O)=O)C1=CC=C(F)C(F)=C1 CWDFHONQSDKIMI-UHFFFAOYSA-N 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- KNLCYAAXQKYIKS-UHFFFAOYSA-N Cl.Cl.Cl.CC1=CC=C(N2CC(N)CC2)C=C1NC(=O)CNC1=CC=C(F)C(F)=C1 Chemical compound Cl.Cl.Cl.CC1=CC=C(N2CC(N)CC2)C=C1NC(=O)CNC1=CC=C(F)C(F)=C1 KNLCYAAXQKYIKS-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- UQUFDVZPPJJQPT-UHFFFAOYSA-N n-[3-[(4-acetylpiperazin-1-yl)methyl]-2-methylphenyl]-2-(3,4-difluoroanilino)acetamide Chemical compound C1CN(C(=O)C)CCN1CC1=CC=CC(NC(=O)CNC=2C=C(F)C(F)=CC=2)=C1C UQUFDVZPPJJQPT-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- LJKLYFNXUIJTKF-UHFFFAOYSA-N tert-butyl 4-[[3-[[2-[3,4-difluoro-n-[(2-methylpropan-2-yl)oxycarbonyl]anilino]acetyl]amino]-4-methylphenyl]methyl]piperazine-1-carboxylate Chemical compound C1=C(NC(=O)CN(C(=O)OC(C)(C)C)C=2C=C(F)C(F)=CC=2)C(C)=CC=C1CN1CCN(C(=O)OC(C)(C)C)CC1 LJKLYFNXUIJTKF-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- KOVQGYQQVNCUBR-UHFFFAOYSA-N (3-methyl-4-nitrophenyl)methanol Chemical compound CC1=CC(CO)=CC=C1[N+]([O-])=O KOVQGYQQVNCUBR-UHFFFAOYSA-N 0.000 description 1
- OQJBFFCUFALWQL-BUHFOSPRSA-N (ne)-n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)\N=N\C(=O)N1CCCCC1 OQJBFFCUFALWQL-BUHFOSPRSA-N 0.000 description 1
- YLBWRMSQRFEIEB-VIFPVBQESA-N 1-[[(2s)-pyrrolidin-2-yl]methyl]pyrrolidine Chemical compound C1CCCN1C[C@@H]1CCCN1 YLBWRMSQRFEIEB-VIFPVBQESA-N 0.000 description 1
- PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical compound CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 description 1
- QTYKWYPHJGMZRN-UHFFFAOYSA-N 2-(3,4-difluoroanilino)-n-[2-methyl-5-[(4-pyrimidin-2-ylpiperazin-1-yl)methyl]phenyl]acetamide Chemical compound C1=C(NC(=O)CNC=2C=C(F)C(F)=CC=2)C(C)=CC=C1CN(CC1)CCN1C1=NC=CC=N1 QTYKWYPHJGMZRN-UHFFFAOYSA-N 0.000 description 1
- YYCKKWSLUGKVSO-KRWDZBQOSA-N 2-(3,4-difluoroanilino)-n-[5-[[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]methyl]-2-methylphenyl]acetamide Chemical compound C1=C(NC(=O)CNC=2C=C(F)C(F)=CC=2)C(C)=CC=C1CN1CCC[C@H]1CO YYCKKWSLUGKVSO-KRWDZBQOSA-N 0.000 description 1
- JKRSQNBRNIYETC-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)propan-1-ol Chemical compound CN1CCN(CCCO)CC1 JKRSQNBRNIYETC-UHFFFAOYSA-N 0.000 description 1
- COORCOHYLVIKTJ-UHFFFAOYSA-N 3-[[2-(3,4-difluoroanilino)acetyl]amino]-n-[2-(dimethylamino)ethyl]-2-methylbenzamide Chemical compound CN(C)CCNC(=O)C1=CC=CC(NC(=O)CNC=2C=C(F)C(F)=CC=2)=C1C COORCOHYLVIKTJ-UHFFFAOYSA-N 0.000 description 1
- FBRXEAZHOYCTQW-UHFFFAOYSA-N 4-(2-tert-butylsilyloxypropan-2-yl)-2-methylaniline Chemical compound C(C)(C)(C)[SiH2]OC(C1=CC(=C(C=C1)N)C)(C)C FBRXEAZHOYCTQW-UHFFFAOYSA-N 0.000 description 1
- DLTKEOYTIZIUKD-UHFFFAOYSA-N 4-(chloromethyl)-1-methyl-2-nitrobenzene Chemical compound CC1=CC=C(CCl)C=C1[N+]([O-])=O DLTKEOYTIZIUKD-UHFFFAOYSA-N 0.000 description 1
- JHFOWEGCZWLHNW-UHFFFAOYSA-N 4-fluoro-2-methyl-1-nitrobenzene Chemical compound CC1=CC(F)=CC=C1[N+]([O-])=O JHFOWEGCZWLHNW-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N C1CCNCC1 Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- QFFSNCDESMMGIQ-GQCTYLIASA-N CCC/C=C(\CF)/F Chemical compound CCC/C=C(\CF)/F QFFSNCDESMMGIQ-GQCTYLIASA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- RXLPAMAJKXAMIZ-UHFFFAOYSA-N Cl.Cl.Cl.C1=C(F)C(F)=CC=C1NCC(=O)NC1=CC(N2CCNCC2)=CC=C1Cl Chemical compound Cl.Cl.Cl.C1=C(F)C(F)=CC=C1NCC(=O)NC1=CC(N2CCNCC2)=CC=C1Cl RXLPAMAJKXAMIZ-UHFFFAOYSA-N 0.000 description 1
- FZAPMZDUDSJAMS-UHFFFAOYSA-N Cl.Cl.Cl.CC1=CC=C(N2CCNCC2)C=C1NC(=O)CNC1=CC=C(F)C(F)=C1 Chemical compound Cl.Cl.Cl.CC1=CC=C(N2CCNCC2)C=C1NC(=O)CNC1=CC=C(F)C(F)=C1 FZAPMZDUDSJAMS-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- 102000016551 L-selectin Human genes 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- 102100037602 P2X purinoceptor 7 Human genes 0.000 description 1
- 101710189965 P2X purinoceptor 7 Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940031993 lithium benzoate Drugs 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- STULOYQZKIGXJD-UHFFFAOYSA-N tert-butyl 4-(3-amino-4-chlorophenyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(Cl)C(N)=C1 STULOYQZKIGXJD-UHFFFAOYSA-N 0.000 description 1
- BBMKAIOZWJLPPF-UHFFFAOYSA-N tert-butyl 4-[(4-methyl-3-nitrophenyl)methyl]piperazine-1-carboxylate Chemical compound C1=C([N+]([O-])=O)C(C)=CC=C1CN1CCN(C(=O)OC(C)(C)C)CC1 BBMKAIOZWJLPPF-UHFFFAOYSA-N 0.000 description 1
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 1
- VTCAXFNALFJCRG-UHFFFAOYSA-N tert-butyl n-(3,4-difluorophenyl)-n-[2-[4-(hydroxymethyl)-2-methylanilino]-2-oxoethyl]carbamate Chemical compound CC1=CC(CO)=CC=C1NC(=O)CN(C(=O)OC(C)(C)C)C1=CC=C(F)C(F)=C1 VTCAXFNALFJCRG-UHFFFAOYSA-N 0.000 description 1
- MSISANCEQBRCBS-UHFFFAOYSA-N tert-butyl n-(3,4-difluorophenyl)-n-[2-[5-(hydroxymethyl)-2-methylanilino]-2-oxoethyl]carbamate Chemical compound CC1=CC=C(CO)C=C1NC(=O)CN(C(=O)OC(C)(C)C)C1=CC=C(F)C(F)=C1 MSISANCEQBRCBS-UHFFFAOYSA-N 0.000 description 1
- UVBRUZYDIQHLTQ-UHFFFAOYSA-N tert-butyl n-[1-(3-methyl-4-nitrophenyl)pyrrolidin-3-yl]carbamate Chemical compound C1=C([N+]([O-])=O)C(C)=CC(N2CC(CC2)NC(=O)OC(C)(C)C)=C1 UVBRUZYDIQHLTQ-UHFFFAOYSA-N 0.000 description 1
- DQQJBEAXSOOCPG-UHFFFAOYSA-N tert-butyl n-pyrrolidin-3-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNC1 DQQJBEAXSOOCPG-UHFFFAOYSA-N 0.000 description 1
- BNPRLRIPNIPHRO-UHFFFAOYSA-N tert-butyl oxolane-2-carboxylate Chemical compound CC(C)(C)OC(=O)C1CCCO1 BNPRLRIPNIPHRO-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9901875A SE9901875D0 (sv) | 1999-05-25 | 1999-05-25 | Novel compounds |
| SE9901875-6 | 1999-05-25 | ||
| PCT/GB2000/001943 WO2000071529A1 (en) | 1999-05-25 | 2000-05-22 | Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003500399A JP2003500399A (ja) | 2003-01-07 |
| JP2003500399A5 true JP2003500399A5 (enExample) | 2007-06-28 |
Family
ID=20415710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000619786A Pending JP2003500399A (ja) | 1999-05-25 | 2000-05-22 | 免疫抑制活性を有する置換フェニル化合物および医薬組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6555541B1 (enExample) |
| EP (1) | EP1185522A1 (enExample) |
| JP (1) | JP2003500399A (enExample) |
| KR (1) | KR20020012583A (enExample) |
| CN (1) | CN1351598A (enExample) |
| AU (1) | AU778305B2 (enExample) |
| BR (1) | BR0010716A (enExample) |
| CA (1) | CA2372580A1 (enExample) |
| IL (2) | IL146187A0 (enExample) |
| MX (1) | MXPA01011957A (enExample) |
| NO (1) | NO322166B1 (enExample) |
| NZ (1) | NZ515282A (enExample) |
| SE (1) | SE9901875D0 (enExample) |
| WO (1) | WO2000071529A1 (enExample) |
| ZA (1) | ZA200109091B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9902270D0 (sv) | 1999-06-16 | 1999-06-16 | Astra Ab | Pharmaceutically active compounds |
| SE9904505D0 (sv) | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
| TWI258462B (en) | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
| SE9904738D0 (sv) * | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
| SE9904765D0 (sv) | 1999-12-23 | 1999-12-23 | Astra Ab | Pharmaceutically-useful compounds |
| US6808924B1 (en) | 2000-07-11 | 2004-10-26 | Claudia Lanari | Mouse mammary tumor lines expressing estrogen and progesterone receptors |
| PA8557501A1 (es) | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
| WO2003042190A1 (en) | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
| JP2006511694A (ja) * | 2002-12-20 | 2006-04-06 | サソル テクノロジー （ピーティーワイ） リミテッド | オレフィンのタンデム四量体化−重合 |
| US7071223B1 (en) * | 2002-12-31 | 2006-07-04 | Pfizer, Inc. | Benzamide inhibitors of the P2X7 receptor |
| PA8591801A1 (es) | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | Inhibidores benzamidicos del receptor p2x7. |
| TWI336696B (en) * | 2003-01-27 | 2011-02-01 | Astellas Pharma Inc | Thiazole derivatives |
| DE10306250A1 (de) | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US7223788B2 (en) | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
| WO2005107804A1 (ja) * | 2004-05-06 | 2005-11-17 | Ono Pharmaceutical Co., Ltd. | 呼吸器疾患治療剤 |
| CN1980902A (zh) * | 2004-06-29 | 2007-06-13 | 辉瑞产品有限公司 | 通过对羟基保护前体去保护而制备5－4－(2－羟基－丙基)－3，5－二氧代－4，5－二氢－3h－[1，2，4]三嗪－2－基－苯甲酰胺衍生物的方法 |
| CA2572118A1 (en) * | 2004-06-29 | 2006-01-12 | Pfizer Products Inc. | Method for preparing 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3h-`1,2,4!-triazin-2-yl!benzamide derivatives with p2x7 inhibiting activity by reaction of the derivative unsubstituted in 4-position of the triazine with an oxiran in the presence of a lewis acid |
| BRPI0512915A (pt) * | 2004-06-29 | 2008-04-15 | Warner Lambert Co | terapias de combinação utilizando inibidores benzamida do receptor p2x7 |
| TWI464148B (zh) | 2006-03-16 | 2014-12-11 | Evotec Us Inc | 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途 |
| CA2645556C (en) | 2006-03-16 | 2016-05-24 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| ES2596532T3 (es) | 2006-03-16 | 2017-01-10 | Second Genome, Inc. | Compuestos de bicicloheteroarilo como moduladores de P2X7 y usos de los mismos |
| US8093265B2 (en) | 2007-03-09 | 2012-01-10 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| AU2009228649B2 (en) | 2008-03-25 | 2014-05-22 | Affectis Pharmaceuticals Ag | Novel P2X7R antagonists and their use |
| DK2243772T3 (da) | 2009-04-14 | 2012-02-13 | Affectis Pharmaceuticals Ag | Hidtil ukendte P2X7R-antagonister og deres anvendelse |
| EP2322149A1 (en) | 2009-11-03 | 2011-05-18 | Universidad del Pais Vasco | Methods and compositions for the treatment of ischemia |
| EP2386541A1 (en) | 2010-05-14 | 2011-11-16 | Affectis Pharmaceuticals AG | Novel methods for the preparation of P2X7R antagonists |
| WO2012027495A1 (en) | 2010-08-27 | 2012-03-01 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| GB2508652A (en) * | 2012-12-07 | 2014-06-11 | Agency Science Tech & Res | Heterocyclic piperazine derivatives |
| CN105712923A (zh) * | 2014-12-03 | 2016-06-29 | 江苏先声药业有限公司 | 一种尼达尼布杂质及其制备方法与应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2623228C3 (de) * | 1976-05-24 | 1981-09-10 | Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren | N-Acyl-substituierte Benzamide, Verfahren zu ihrer Herstellung und Arzneimittel, enthaltend solche Benzamide |
| DE2730174C2 (de) * | 1977-07-04 | 1981-12-10 | Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren | Aminobenzoesäurederivate und Arzneimittel enthaltend solche Aminobenzoesäurederivate |
| JPS57171904A (en) * | 1981-04-15 | 1982-10-22 | Mitsubishi Petrochem Co Ltd | Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide |
| CA1169691A (en) * | 1981-07-06 | 1984-06-26 | Max H. Stern | Color-forming para-sulfonamidodiphenylamine dye precursor and sulfonimide dye in photographic material and process |
| JPS62253168A (ja) * | 1986-04-25 | 1987-11-04 | Konika Corp | 色素画像の安定性を改良したハロゲン化銀写真感光材料 |
| JPS62291653A (ja) * | 1986-06-11 | 1987-12-18 | Konica Corp | ハロゲン化銀写真感光材料 |
| JPH0660145B2 (ja) * | 1989-02-09 | 1994-08-10 | 東洋紡績株式会社 | 新規置換アセトアミド化合物 |
| AU6267198A (en) * | 1997-02-14 | 1998-09-08 | Bayer Corporation | Amides as npy5 receptor antagonists |
| JPH1171336A (ja) * | 1997-06-25 | 1999-03-16 | Mitsubishi Chem Corp | アミド誘導体 |
| SE9704546D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| JP4261639B2 (ja) * | 1998-08-05 | 2009-04-30 | 日本曹達株式会社 | フェニルイミダゾール系抗高脂血症薬 |
-
1999
- 1999-05-25 SE SE9901875A patent/SE9901875D0/xx unknown
-
2000
- 2000-05-22 BR BR0010716-6A patent/BR0010716A/pt not_active Application Discontinuation
- 2000-05-22 KR KR1020017015027A patent/KR20020012583A/ko not_active Ceased
- 2000-05-22 CA CA002372580A patent/CA2372580A1/en not_active Abandoned
- 2000-05-22 MX MXPA01011957A patent/MXPA01011957A/es active IP Right Grant
- 2000-05-22 EP EP00931406A patent/EP1185522A1/en not_active Withdrawn
- 2000-05-22 US US09/583,000 patent/US6555541B1/en not_active Expired - Fee Related
- 2000-05-22 IL IL14618700A patent/IL146187A0/xx active IP Right Grant
- 2000-05-22 NZ NZ515282A patent/NZ515282A/xx unknown
- 2000-05-22 JP JP2000619786A patent/JP2003500399A/ja active Pending
- 2000-05-22 WO PCT/GB2000/001943 patent/WO2000071529A1/en not_active Ceased
- 2000-05-22 AU AU49362/00A patent/AU778305B2/en not_active Ceased
- 2000-05-22 CN CN00808036A patent/CN1351598A/zh active Pending
-
2001
- 2001-10-25 IL IL146187A patent/IL146187A/en not_active IP Right Cessation
- 2001-11-02 ZA ZA200109091A patent/ZA200109091B/xx unknown
- 2001-11-20 NO NO20015665A patent/NO322166B1/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6555541B1 (en) | Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions | |
| JP3880842B2 (ja) | １−〔（４−クロロフェニル）フェニルメチル〕ピペラジンの鏡像体およびその製造法 | |
| EP1786773A1 (en) | Isoindolin-1-one derivatives | |
| HU184966B (en) | Process for producing phenyl-piperazine derivatives of anti-agression activity | |
| EA018032B1 (ru) | Производные фенилсульфамоилбензамидов в качестве антагонистов брадикининовых рецепторов, способ их получения и фармацевтическая композиция, их содержащая | |
| JPH01102078A (ja) | ビスピジン誘導体及びこれを含有する抗不整脈剤 | |
| US5872119A (en) | 2-Naphthamide derivatives and their therapeutic applications | |
| HU202211B (en) | Process for producing new imidazoline derivatives and pharmaceutical compositions containing them as active components | |
| EP0222533A1 (en) | Cis-N-[(2-aminocycloaliphatic)benzene acetamide and -benzamide anticonvulsants | |
| EP0325406B1 (en) | Diamine compounds | |
| JP3853653B2 (ja) | カルボン酸アミド、その調製法及び医薬組成物としてのその使用 | |
| TWI360540B (en) | Tetrahydroisoquinolylsulphonamide derivatives, the | |
| EP0221511B1 (en) | 2-aminosulfonyl-6-nitrobenzoic esters or amides, process for their preparation and pharmaceutical compositions containing them | |
| US5238962A (en) | Benzamide derivatives | |
| HU199409B (en) | Process for producing n-(substituted phenyl)-benzoilamide derivatives and pharmaceutical compositions with antispasmodic effect and comprising the compounds | |
| JPH09501954A (ja) | イミダゾ［５，１−ｃ］［１，４］ベンゾキサジン−１−オンのイミダゾリルアルキル誘導体およびそれらの製造法 | |
| JPS61215361A (ja) | 抗痙攣剤 | |
| EP0197386B1 (en) | 2-(substituted sulfamyl) derivatives of 6-nitrobenzoic acid, process for their preparation and pharmaceutical compositions containing them | |
| JP3786983B2 (ja) | ピロリジノン誘導体 | |
| EP1511728B1 (fr) | Derives d oxophenyl-cyclohexyl-propanolamine, leur preparati on et leur application en therapeutique | |
| US4694020A (en) | Derivatives of 2-(substituted sulfamyl)-6-nitrobenzoic acids and pharmaceutical compositions | |
| FR2816619A1 (fr) | Derives de benzimidazole, leur preparation et leur application en therapeutique | |
| US4610991A (en) | Antihypertensive pyridylaminobenzamide compounds | |
| Demers Jr et al. | Synthesis of diphenic acid derivatives | |
| US3660461A (en) | N-cycloalkyl-n'-cyanoalkyl alkoxybenzamides |